New use of microsatellite instability analysis in endometrial cancer (Review)

Haruko Kunitomi, Kouji Banno, Megumi Yanokura, Takashi Takeda, Moito Iijima, Kanako Nakamura, Miho Iida, Masataka Adachi, Keiko Watanabe, Yusuke Matoba, Yusuke Kobayashi, Eiichirou Tominaga, Daisuke Aoki

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

The increasing incidence of obesity and diabetes due to changes in diet, earlier menarche, delayed menopause, late marriage, and declining birth rate have resulted in an increase in the number of endometrial cancer cases over the last few decades. Although surgical therapy is sufficient for early endometrial cancer, there is no effective therapy for patients with advanced and recurrent endometrial cancer. The oncogenic mechanism of endometrial cancer involves microsatellite instability (MSI) caused by dysfunction of DNA mismatch repair genes in 30% of patients. Immune checkpoint inhibitors, including anti-programmed death (PD)-1 and anti-PD-ligand 1 antibodies, are of interest as novel anticancer drugs; however, these drugs are currently expensive, and there is a need to select patients who will benefit from their use. The use of MSI analysis as a predictive biomarker for the therapeutic efficacy of these drugs may be useful for reducing the costs of drug therapy.

Original languageEnglish
Pages (from-to)3297-3301
Number of pages5
JournalOncology Letters
Volume14
Issue number3
DOIs
Publication statusPublished - 2017

Fingerprint

Microsatellite Instability
Endometrial Neoplasms
Pharmaceutical Preparations
Menarche
DNA Mismatch Repair
Birth Rate
Menopause
Marriage
Therapeutics
Obesity
Biomarkers
Diet
Ligands
Costs and Cost Analysis
Drug Therapy
Antibodies
Incidence
Genes

Keywords

  • Biomarker
  • Endometrial cancer
  • Immune checkpoint inhibitor
  • Microsatellite instability
  • Mismatch repair

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

New use of microsatellite instability analysis in endometrial cancer (Review). / Kunitomi, Haruko; Banno, Kouji; Yanokura, Megumi; Takeda, Takashi; Iijima, Moito; Nakamura, Kanako; Iida, Miho; Adachi, Masataka; Watanabe, Keiko; Matoba, Yusuke; Kobayashi, Yusuke; Tominaga, Eiichirou; Aoki, Daisuke.

In: Oncology Letters, Vol. 14, No. 3, 2017, p. 3297-3301.

Research output: Contribution to journalReview article

Kunitomi, H, Banno, K, Yanokura, M, Takeda, T, Iijima, M, Nakamura, K, Iida, M, Adachi, M, Watanabe, K, Matoba, Y, Kobayashi, Y, Tominaga, E & Aoki, D 2017, 'New use of microsatellite instability analysis in endometrial cancer (Review)', Oncology Letters, vol. 14, no. 3, pp. 3297-3301. https://doi.org/10.3892/ol.2017.6640
Kunitomi, Haruko ; Banno, Kouji ; Yanokura, Megumi ; Takeda, Takashi ; Iijima, Moito ; Nakamura, Kanako ; Iida, Miho ; Adachi, Masataka ; Watanabe, Keiko ; Matoba, Yusuke ; Kobayashi, Yusuke ; Tominaga, Eiichirou ; Aoki, Daisuke. / New use of microsatellite instability analysis in endometrial cancer (Review). In: Oncology Letters. 2017 ; Vol. 14, No. 3. pp. 3297-3301.
@article{a67c11c61fc2483cb14f6e7d150be6cb,
title = "New use of microsatellite instability analysis in endometrial cancer (Review)",
abstract = "The increasing incidence of obesity and diabetes due to changes in diet, earlier menarche, delayed menopause, late marriage, and declining birth rate have resulted in an increase in the number of endometrial cancer cases over the last few decades. Although surgical therapy is sufficient for early endometrial cancer, there is no effective therapy for patients with advanced and recurrent endometrial cancer. The oncogenic mechanism of endometrial cancer involves microsatellite instability (MSI) caused by dysfunction of DNA mismatch repair genes in 30{\%} of patients. Immune checkpoint inhibitors, including anti-programmed death (PD)-1 and anti-PD-ligand 1 antibodies, are of interest as novel anticancer drugs; however, these drugs are currently expensive, and there is a need to select patients who will benefit from their use. The use of MSI analysis as a predictive biomarker for the therapeutic efficacy of these drugs may be useful for reducing the costs of drug therapy.",
keywords = "Biomarker, Endometrial cancer, Immune checkpoint inhibitor, Microsatellite instability, Mismatch repair",
author = "Haruko Kunitomi and Kouji Banno and Megumi Yanokura and Takashi Takeda and Moito Iijima and Kanako Nakamura and Miho Iida and Masataka Adachi and Keiko Watanabe and Yusuke Matoba and Yusuke Kobayashi and Eiichirou Tominaga and Daisuke Aoki",
year = "2017",
doi = "10.3892/ol.2017.6640",
language = "English",
volume = "14",
pages = "3297--3301",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - New use of microsatellite instability analysis in endometrial cancer (Review)

AU - Kunitomi, Haruko

AU - Banno, Kouji

AU - Yanokura, Megumi

AU - Takeda, Takashi

AU - Iijima, Moito

AU - Nakamura, Kanako

AU - Iida, Miho

AU - Adachi, Masataka

AU - Watanabe, Keiko

AU - Matoba, Yusuke

AU - Kobayashi, Yusuke

AU - Tominaga, Eiichirou

AU - Aoki, Daisuke

PY - 2017

Y1 - 2017

N2 - The increasing incidence of obesity and diabetes due to changes in diet, earlier menarche, delayed menopause, late marriage, and declining birth rate have resulted in an increase in the number of endometrial cancer cases over the last few decades. Although surgical therapy is sufficient for early endometrial cancer, there is no effective therapy for patients with advanced and recurrent endometrial cancer. The oncogenic mechanism of endometrial cancer involves microsatellite instability (MSI) caused by dysfunction of DNA mismatch repair genes in 30% of patients. Immune checkpoint inhibitors, including anti-programmed death (PD)-1 and anti-PD-ligand 1 antibodies, are of interest as novel anticancer drugs; however, these drugs are currently expensive, and there is a need to select patients who will benefit from their use. The use of MSI analysis as a predictive biomarker for the therapeutic efficacy of these drugs may be useful for reducing the costs of drug therapy.

AB - The increasing incidence of obesity and diabetes due to changes in diet, earlier menarche, delayed menopause, late marriage, and declining birth rate have resulted in an increase in the number of endometrial cancer cases over the last few decades. Although surgical therapy is sufficient for early endometrial cancer, there is no effective therapy for patients with advanced and recurrent endometrial cancer. The oncogenic mechanism of endometrial cancer involves microsatellite instability (MSI) caused by dysfunction of DNA mismatch repair genes in 30% of patients. Immune checkpoint inhibitors, including anti-programmed death (PD)-1 and anti-PD-ligand 1 antibodies, are of interest as novel anticancer drugs; however, these drugs are currently expensive, and there is a need to select patients who will benefit from their use. The use of MSI analysis as a predictive biomarker for the therapeutic efficacy of these drugs may be useful for reducing the costs of drug therapy.

KW - Biomarker

KW - Endometrial cancer

KW - Immune checkpoint inhibitor

KW - Microsatellite instability

KW - Mismatch repair

UR - http://www.scopus.com/inward/record.url?scp=85026316553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026316553&partnerID=8YFLogxK

U2 - 10.3892/ol.2017.6640

DO - 10.3892/ol.2017.6640

M3 - Review article

VL - 14

SP - 3297

EP - 3301

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 3

ER -